Telmisartan inhibits the progression of cardiomyopathy in daunorubicin treated rats: The role of advanced glycation end products

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: Anthracyclines have been reported to induce cardiotoxicity through mechanisms involving formation of advanced glycation end-products (AGEs), including pentosidine and Nє-(carboxymethyl) lysine (CML). We investigated the potential utility of telmisartan (TML), an angiotensin II receptor antagonists (ARB) on anthracycline-induced cardiotoxicity. Methods: Three groups of Sprague-Dawley rats were treated as follows: The first group received daunorubicin (DNR) 3 mg/kgBW every alternating day to reach a cumulative dose of 9 mg/kg DNR. The second group received DNR plus TLM at a dose10 mg/kgBW, by oral gavage for 6 weeks, and the third group served as control group (CTL) which only received vehicle of DNR. Mean blood pressure (MBP) peak left ventricular pressure (LVP), LV end-diastolic pressure (LVEDP), and intra-ventricular contractility (±dP/dt) were recorded by using Powerlab instrumentation. Ejection fraction (EF), and fractional shortening (FS) were measured by echocardiography. Expression of receptor of AGE (RAGE), pentosidine and CML were measured by immunohistochemistry and Western blot in LV tissue. Results: DNR treatment was associated with significant weakening of some hemodynamic parameters which could be reversed by TML (LVP: 124.3 ± 6.0; 111 ± 7; and 115.1 ± 5.4 mmHg, respectively in CTL, DNR and DNR-TLM groups; LVEDP: 7.5 ± 0.9; 10.7 ± 0.3; 8.7 ± 0.4 mmHg, respectively; +dP/dt: 6813 ± 541; 4800 ± 345; 5950 ± 398 mmHg/s, respectively). The same phenomenons were also observed on echocardiographic parameters (EF: 78.9 ± 1.8; 59.6 ± 1.4; 76.2 ± 2.75%, resepectively; FS: 42.8 ± 1.7; 29.1 ± 1.3; 41 ± 2.7%) respectively. Expression of RAGE as well as pentosidine and CML were increased in DNR-rats. TML treatment ameliorated these changes. Conclusion: These results suggested the role of AGE formation in DNR-induced cardiotoxicity and telmisartan could inhibit the progression of cardiac toxicity at least in part by reduction RAGE expressiom.

References Powered by Scopus

Measurement of protein using bicinchoninic acid

19895Citations
N/AReaders
Get full text

Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPARγ-Modulating Activity

1086Citations
N/AReaders
Get full text

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

677Citations
N/AReaders
Get full text

Cited by Powered by Scopus

6-gingerol ameliorated doxorubicin-induced cardiotoxicity: Role of nuclear factor kappa B and protein glycation

45Citations
N/AReaders
Get full text

Recent updates on current and upcoming biomarkers for cardiovascular diseases

6Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Arozal, W., Watanabe, K., Veeraveedu, P. T., Ma, M., & Nafrialdi. (2011). Telmisartan inhibits the progression of cardiomyopathy in daunorubicin treated rats: The role of advanced glycation end products. Medical Journal of Indonesia, 20(4), 255–262. https://doi.org/10.13181/mji.v20i4.461

Readers' Seniority

Tooltip

Lecturer / Post doc 2

33%

PhD / Post grad / Masters / Doc 2

33%

Professor / Associate Prof. 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Pharmacology, Toxicology and Pharmaceut... 2

29%

Chemistry 1

14%

Veterinary Science and Veterinary Medic... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free